Cara Therapeutics, Inc. (CARA)
15.96
-0.69 (-4.14%)
Inactive · Last trade price
on Apr 15, 2025
Cara Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 2.81 | 20.27 | 41.87 | 23.03 | 135.08 | Upgrade
|
| Other Revenue | 4.33 | 0.7 | - | - | - | Upgrade
|
| Revenue | 7.14 | 20.97 | 41.87 | 23.03 | 135.08 | Upgrade
|
| Revenue Growth (YoY) | -65.96% | -49.92% | 81.81% | -82.95% | 579.28% | Upgrade
|
| Cost of Revenue | 36.39 | 113.55 | 98.01 | 81.56 | 107.07 | Upgrade
|
| Gross Profit | -29.25 | -92.58 | -56.14 | -58.54 | 28.01 | Upgrade
|
| Selling, General & Admin | 26.53 | 28.92 | 31.39 | 30.55 | 22.63 | Upgrade
|
| Operating Expenses | 26.53 | 28.92 | 31.39 | 30.55 | 22.63 | Upgrade
|
| Operating Income | -55.78 | -121.5 | -87.54 | -89.08 | 5.39 | Upgrade
|
| Interest Expense | -8.47 | -0.6 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.29 | 3.19 | 2.33 | 1.39 | 2.22 | Upgrade
|
| EBT Excluding Unusual Items | -61.97 | -118.91 | -85.21 | -87.69 | 7.6 | Upgrade
|
| Merger & Restructuring Charges | -5.57 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.54 | 0.4 | -0.26 | -0.82 | 0.12 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.07 | - | Upgrade
|
| Asset Writedown | -4.27 | - | - | - | - | Upgrade
|
| Pretax Income | -71.27 | -118.51 | -85.47 | -88.44 | 7.72 | Upgrade
|
| Income Tax Expense | -0.4 | - | - | - | -0.69 | Upgrade
|
| Net Income | -70.87 | -118.51 | -85.47 | -88.44 | 8.41 | Upgrade
|
| Net Income to Common | -70.87 | -118.51 | -85.47 | -88.44 | 8.41 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 2 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 1.11% | 0.92% | 5.79% | 5.85% | 12.29% | Upgrade
|
| EPS (Basic) | -46.60 | -78.79 | -57.35 | -62.78 | 6.39 | Upgrade
|
| EPS (Diluted) | -46.60 | -78.79 | -57.36 | -62.78 | 6.39 | Upgrade
|
| Free Cash Flow | -61.96 | -94.45 | -78.77 | -60.13 | -5.84 | Upgrade
|
| Free Cash Flow Per Share | -40.74 | -62.80 | -52.85 | -42.68 | -4.38 | Upgrade
|
| Gross Margin | - | - | -134.09% | -254.19% | 20.74% | Upgrade
|
| Operating Margin | -781.58% | -579.43% | -209.08% | -386.85% | 3.99% | Upgrade
|
| Profit Margin | -992.95% | -565.21% | -204.16% | -384.06% | 6.23% | Upgrade
|
| Free Cash Flow Margin | -868.19% | -450.46% | -188.15% | -261.10% | -4.32% | Upgrade
|
| EBITDA | -55.59 | -121.24 | -87.29 | -88.84 | 5.59 | Upgrade
|
| EBITDA Margin | - | - | -208.49% | - | 4.14% | Upgrade
|
| D&A For EBITDA | 0.19 | 0.26 | 0.25 | 0.25 | 0.21 | Upgrade
|
| EBIT | -55.78 | -121.5 | -87.54 | -89.08 | 5.39 | Upgrade
|
| EBIT Margin | - | - | -209.08% | - | 3.99% | Upgrade
|
| Revenue as Reported | 7.14 | 20.97 | 41.87 | 23.03 | 135.08 | Upgrade
|
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.